Regulus Therapeutics Stock Today
| RGLS Stock | USD 1.61 0.03 1.83% |
Performance2 of 100
| Odds Of DistressLess than 41
|
Regulus Therapeutics is selling for under 1.61 as of the 30th of November 2024; that is 1.83 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.54. Regulus Therapeutics has about a 41 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Regulus Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of October 2012 | Category Healthcare | Classification Health Care |
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. The company has 65.5 M outstanding shares of which 1.64 M shares are at this time shorted by private and institutional investors with about 3.63 trading days to cover. More on Regulus Therapeutics
Moving against Regulus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Regulus Stock Highlights
| CEO Director | Joseph MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRegulus Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Regulus Therapeutics' financial leverage. It provides some insight into what part of Regulus Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regulus Therapeutics (RGLS) is traded on NASDAQ Exchange in USA. It is located in 4224 Campus Point Court, San Diego, CA, United States, 92121 and employs 32 people. Regulus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 107.42 M. Regulus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 65.5 M outstanding shares of which 1.64 M shares are at this time shorted by private and institutional investors with about 3.63 trading days to cover.
Regulus Therapeutics currently holds about 47.53 M in cash with (26.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.25, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Regulus Therapeutics Probability Of Bankruptcy
Ownership AllocationRegulus Therapeutics owns a total of 65.5 Million outstanding shares. The majority of Regulus Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Regulus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Regulus Therapeutics. Please pay attention to any change in the institutional holdings of Regulus Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Regulus Ownership Details
Regulus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Woodline Partners Lp | 2024-06-30 | 947.7 K | |
| Dafna Capital Management Llc | 2024-09-30 | 895.2 K | |
| Point72 Asset Management, L.p. | 2024-09-30 | 893.8 K | |
| Ra Capital Management, Llc | 2024-09-30 | 766.8 K | |
| Opaleye Management Inc | 2024-09-30 | 535 K | |
| Northern Trust Corp | 2024-09-30 | 497.3 K | |
| Cvi Holdings Llc | 2024-06-30 | 401 K | |
| Victory Capital Management Inc. | 2024-09-30 | 398.9 K | |
| Fmr Inc | 2024-09-30 | 328.2 K | |
| Federated Hermes Inc | 2024-09-30 | 12.9 M | |
| Vivo Capital, Llc | 2024-09-30 | 5 M |
Regulus Therapeutics Historical Income Statement
Regulus Stock Against Markets
Regulus Therapeutics Corporate Management
| Christopher JD | General VP | Profile | |
| MS MT | VP Operations | Profile | |
| MS MD | Senior Regulatory | Profile | |
| Crispina CPA | Chief Officer | Profile | |
| Denis Drygin | Chief Officer | Profile | |
| Firuz Shakoori | Head CMC | Profile |
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.